Exchange: BATS·Updated 11:22 AM EDT

ARKG News

News
all
press releases
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027.
Stocktwits
More News
What Is Cathie Wood Buying Now? Nvidia, SpaceX And Crypto Stocks Led ARK’s August Trades – While Cutting These Growth Stocks
Nvidia was ARK’s biggest August purchase, with roughly 548,000 shares added during the month.
Stocktwits
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.
Stocktwits
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
Stocktwits
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.
Stocktwits
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing
Multiple analysts reiterated optimism on CMPS stock after the company announced 26-week data from its second late-stage trial of COMP360 in treatment-resistant depression.
Stocktwits
Best ETF Areas of June
Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.
Zacks
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise
Absci Corporation said that its drug ABS-201 was well-tolerated and showed a long-lasting presence in the body in a clinical trial.
Stocktwits
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
Zacks

Advertisement|Remove ads.